Gossamer Bio Inc (NAS:GOSS)
$ 0.6385 -0.0315 (-4.7%) Market Cap: 144.44 Mil Enterprise Value: 116.22 Mil PE Ratio: 0 PB Ratio: 5.32 GF Score: 37/100

Gossamer Bio Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 10, 2021 / 06:50PM GMT
Release Date Price: $9.99 (+4.17%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Okay. Good afternoon and welcome to day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. Our next session is with Gossamer Bio. Representing the company, we got a full squad today, CEO, Faheem Hasnain; Richard Aranda, heading up Clinical; Bryan Giraudo from IR; and Jill Howe from the finance team. Everyone, welcome. Thank you for joining us today.

Richard Aranda
Gossamer Bio, Inc. - SVP of Clinical Development

Thank you.

Faheem Hasnain
Gossamer Bio, Inc. - Co-Founder, CEO, President & Chairman

Happy to be here.

Questions & Answers

Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Great. Faheem, as we get started, I thought as you -- I was going to ask you to maybe just offer some comments and sort of set up the pipeline as you think about it now. But as we were talking before we got started,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot